Nasdaq:US$32.17 (-0.06) | HKEX:HK$50.45 (+0.80) | AIM:£4.69 (+0.01)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2014-06-03

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors